Navigation Links
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Date:4/14/2008

nc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Micromet Announces Changes in Management Team
5. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
6. VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
7. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
8. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
9. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , UNION CITY, Calif., Nov. 25 /PRNewswire-Fir...l products company manufacturing point-of-care blo...verson, chairman and chief executive officer, will...are Conference on Wednesday, December 2, 2009 at 2...w York Palace Hotel in New York City. ,, About...
(Date:11/25/2009)... , CHAPEL HILL, N.C., Nov. 25 /PRNewswire...hat Prabhavathi Fernandes, president and chief exe...21st Annual Health Care Conference at 8:50 a.m. ES...in New York City. Dr. Fernandes will provide an o...inical programs for the treatment of drug-resistan...
(Date:11/25/2009)... , FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /P...nc. (Nasdaq: HTWR ; ASX: HIN), a leading innovato...ulatory support technologies revolutionizing the t...d that it is scheduled to make an investor present... Conference at 8:00 am EST on Wednesday, December ...
Breaking Medicine Technology:HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2PTS Inc Subsidiary Disability Access Corporation Announces 24535 000 in New Contracts and Inspection Orders for July 2009 52196 1PTS Inc Subsidiary Disability Access Corporation Announces 24535 000 in New Contracts and Inspection Orders for July 2009 52196 2BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 1BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 2BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 3Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4757 1Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4757 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4757 3
...te early non-responders unlikely to subsequently,r...nd may benefit,from earlier change in treatment st...RNewswire-FirstCall/,-- New data presented at the ...rch (ICOSR) suggest that antipsychotic drug,respon...and,challenge the current schizophrenia treatment ...
...ced By an Average of More Than Two Hours Per Day, ...wswire/ --,Adding the once daily, investigational ...M) Extended-Release Tablets to,Parkinson,s patient...y reduced ,off, time, allowing patients to continu...me. ,Off time,describes the return of Parkinson,s...
Other Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:11/28/2009)...variation believed to affect circadian rhythm, ...- New research suggests that an internal body cloc...development of bipolar disorder in children. ,...enetic makeup of 152 children with bipolar disorde... swings, and 140 children without the disorder. Th...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued ...genomic data. It shows that the lethality of the ...during the virus,s current outbreak in the spring ...f 2.0 (s.d. 0.1). The H1N1 infectivity count, howe... Boston (PRWEB) November 27, 2009 -- Biotech firm ...
(Date:11/27/2009)...ILLY-SUR-SEINE, France, Nov. 27 Te...nal cycling team dedicated to ethical sporting and...ns, announced today that it will become Team Garmi...ical as a new sponsor of the team. Transitions Opt...ve eyewear, offering the most advanced photochromi...
(Date:11/27/2009)...bring unprecedented medical, economic burdens, stu...ay News) -- The number of people with diabetes in ...ext 25 years, a new study predicts. , That woul...ople with the disease, up from 23.7 million today....le with diabetes will triple, the study also warns...
(Date:11/27/2009)... Specialist manufacturers who use medical ...ng millions of dollars by bringing in technology p...sing numbers of pro-active medical manufacturers a...cept stage of their projects, ensuring that progre...esses or potentially outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...ol Uniquely Provides Minute-by-Minute and Trend In...ve Diabetes Management, ABBOTT PARK, Ill., March ...roved the FreeStyle Navigator(R) Continuous,Glucos...re glucose levels through a sensor in the back of ...
...ctured majority of convertible notes due June 2008... forward Projects Zevalin(R) net sales revenue...tle-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; ... completion of Zevalin(R) (Ibritumomab Tiuxetan) a...
...Therapeutics, Inc., leaders in light therapy, prou...A approval, CARLSBAD, Calif., March 12 Photo The...ived FDA approval on its new,over-the-counter ligh... New-U has been clinically proven to reduce perior...
...ent from Georges C. Benjamin, MD, FACP, FACEP (E),...ation, WASHINGTON, March 12 The U.S. Environment...otective National Ambient,Air Quality Standards (N...c Health Association (APHA) is concerned that,the ...
...in poor neighborhoods most likely to watch TVs or ...h 12 (HealthDay News) -- A new survey reports that...t of TVs and computers, and those in poor neighbor...heir neighborhoods," said study author Tracie A. B...
...Sponsor a Recipient of American Academy of Nursing...are Research, SACRAMENTO, Calif., March 12 A stu...-to-patient staffing ratios in California,hospital...itics & Nursing Practice, a peer-reviewed journal ...
Other Medicine News:Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 2Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 3Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 4Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 5Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Omnilux New-U(TM) Hand-Held Device Receives FDA Approval 2Health News:APHA Says New Ozone Regulations a Missed Opportunity to Protect Public's Health 2Health News:Teens Spending Too Much Screen Time 2Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 2Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 4
Back Relief Apron
Surgical Drop-Off Apron
Wrap-Around Back Relief
Vest-Skirt Combination
Medicine Products: